IART Integra Lifesciences Holdings Corp

Price (delayed)

$70.55

Market cap

$5.97B

P/E Ratio

29.15

Dividend/share

N/A

EPS

$2.42

Enterprise value

$7.22B

Integra LifeSciences is a global leader in regenerative tissue technologies and neurosurgical solutions dedicated to limiting uncertainty for clinicians, so they can focus on providing the best patient care. Integra ...

Highlights
The stock's price to earnings (P/E) is 54% less than its 5-year quarterly average of 63.8 and 33% less than its last 4 quarters average of 43.5
Integra Lifesciences Holdings's net income has increased by 21% from the previous quarter
IART's quick ratio is up by 29% from the previous quarter but it is down by 22% YoY

Key stats

What are the main financial stats of IART
Market
Shares outstanding
84.58M
Market cap
$5.97B
Enterprise value
$7.22B
Valuations
Price to earnings (P/E)
29.15
Price to book (P/B)
3.79
Price to sales (P/S)
3.96
EV/EBIT
28.13
EV/EBITDA
19.18
EV/Sales
4.79
Earnings
Revenue
$1.51B
EBIT
$256.75M
EBITDA
$376.65M
Free cash flow
$282.16M
Per share
EPS
$2.42
Free cash flow per share
$3.33
Book value per share
$18.63
Revenue per share
$17.82
TBVPS
$17.93
Balance sheet
Total assets
$3.71B
Total liabilities
$2.14B
Debt
$1.65B
Equity
$1.57B
Working capital
$713.63M
Liquidity
Debt to equity
1.05
Current ratio
3.24
Quick ratio
1.97
Net debt/EBITDA
3.33
Margins
EBITDA margin
25%
Gross margin
61.6%
Net margin
13.6%
Operating margin
12.8%
Efficiency
Return on assets
5.7%
Return on equity
13.7%
Return on invested capital
10.3%
Return on capital employed
7.6%
Return on sales
17%
Dividend
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A

IART stock price

How has the Integra Lifesciences Holdings stock price performed over time
Intraday
-0.38%
1 week
4.27%
1 month
-2.26%
1 year
43.77%
YTD
8.67%
QTD
3.02%

Financial performance

How have Integra Lifesciences Holdings's revenue and profit performed over time
Revenue
$1.51B
Gross profit
$929.97M
Operating income
$192.76M
Net income
$205.54M
Gross margin
61.6%
Net margin
13.6%
The operating income has grown by 24% since the previous quarter
Integra Lifesciences Holdings's net income has increased by 21% from the previous quarter
IART's operating margin is up by 14% since the previous quarter
The net margin is up by 11% since the previous quarter

Growth

What is Integra Lifesciences Holdings's growth rate over time

Valuation

What is Integra Lifesciences Holdings stock price valuation
P/E
29.15
P/B
3.79
P/S
3.96
EV/EBIT
28.13
EV/EBITDA
19.18
EV/Sales
4.79
The stock's price to earnings (P/E) is 54% less than its 5-year quarterly average of 63.8 and 33% less than its last 4 quarters average of 43.5
IART's EPS is up by 20% since the previous quarter
The equity has increased by 17% year-on-year and by 3% since the previous quarter
The P/B is 8% higher than the last 4 quarters average of 3.5 and 5% higher than the 5-year quarterly average of 3.6
The price to sales (P/S) is 16% more than the 5-year quarterly average of 3.4 and 7% more than the last 4 quarters average of 3.7
The revenue is up by 10% since the previous quarter and by 9% year-on-year

Efficiency

How efficient is Integra Lifesciences Holdings business performance
IART's return on invested capital is up by 20% since the previous quarter
IART's ROA is up by 19% QoQ
Integra Lifesciences Holdings's return on equity has increased by 17% QoQ
IART's return on sales is up by 8% since the previous quarter

Dividends

What is IART's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A

There are no recent dividends present for IART.

Financial health

How did Integra Lifesciences Holdings financials performed over time
The company's total assets is 74% higher than its total liabilities
IART's quick ratio is up by 29% from the previous quarter but it is down by 22% YoY
The current ratio has declined by 29% year-on-year but it has grown by 29% since the previous quarter
The debt is 4.9% greater than the equity
The equity has increased by 17% year-on-year and by 3% since the previous quarter
Integra Lifesciences Holdings's debt to equity has decreased by 15% YoY and by 8% QoQ

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.